Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04515056
Other study ID # N-20200005
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 1, 2020
Est. completion date June 1, 2021

Study information

Verified date July 2021
Source Aalborg University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this experiment the investigators would like to test a new new human itch model based on papain, and to characterize the sensory quality and temporary aspects of papain skin prick test (SPT) in comparison to the inactivated-cowhage delivery system.


Description:

The most used model of non-histaminergic itch is cowhage but this models presents several problems, such us the impossibility of standardizing the amount of the spicules inserted in the skin and the difficulty of obtaining the substance. These aspects bring us the necessity to find a new and more standardized model of non-histaminergic itch. Papain is a cysteine protease extracted from papaya plant that is known to cause itch if applied to the skin. For these reasons the investigators would like to test a new new human itch model based on papain, and to characterize the sensory quality and temporary aspects of papain skin prick test (SPT) in comparison to the inactivated-cowhage delivery system.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date June 1, 2021
Est. primary completion date June 1, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Healthy men and women - 18-60 years - Speak and understand English Exclusion Criteria: - Pregnancy or lactation - Drug addiction defined as any use of cannabis, opioids or other addictive drugs - Previous or current history of neurological, dermatological, immunological musculoskeletal, cardiac disorder or mental illnesses that may affect the results (e.g. neuropathy, muscular pain in the upper extremities, etc.). - Lack of ability to cooperate - Current use of medications that may affect the trial such as antihistamines, antipsychotics and pain killers, as well as systemic or topical steroids. - Skin diseases - Moles, scars or tattoos in the area to be treated or tested. - Hypersensitivity to papaya and mango fruit, cashew nuts, rubber latex - Consumption of alcohol or painkillers 24 hours before the study days and between these - Acute or chronic pain - Participation in other trials within 1 week of study entry (4 weeks in the case of pharmaceutical trials)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Papain 10 µg
The area will be exposed to 10 µg of papain.
Papain 50 µg
The area will be exposed to 50 µg of papain.
Papain 100 µg
The area will be exposed to 100 µg of papain.
Other:
Vehicle
The area will be exposed to vehicle
Drug:
Papain 1 SPT
Papain will be applied by 1 SPT prick thought the skin
Papain 5 SPT
Papain will be applied by 5 SPT pricks thought the skin
Papain 25 SPT
Papain will be applied by 25 SPT pricks thought the skin
Other:
Cowhage
The last area will be exposed to cowage spicules (made chemically inert by autoclaving) soaked in 5 mg/ml papain solution.

Locations

Country Name City State
Denmark Aalborg University Aalborg Nordjylland

Sponsors (1)

Lead Sponsor Collaborator
Aalborg University

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Superficial blood perfusion Superficial blood perfusion is measured by a Speckle contrast imager (FLPI, Moor Instruments, England). 15 minutes
Primary Measuring itch intensity by computerized Visual Analog Scale Scoring The subjects will rate the sensation of itch on a 100 mm VAS scale ranging from 0 to 100 where 0 indicates "no itch" and 100 indicates "worst itch imaginable" and similarly for sensations of stinging/pricking and burning, both of which are frequently associated with the sensation of itch. 15 minutes
Primary Measuring pain intensity by computerized Visual Analog Scale Scoring The subjects will rate the sensation of pain on a 100 mm VAS scale ranging from 0 to 100 where 0 indicates "no pain" and 100 indicates "worst pain imaginable". 15 minutes
Primary Measuring Alloknesis Alloknesis is measured by using mildly pruritic, non-painful von Frey nylon filaments of a predetermined intensity (generally 5-30 milliNewton of force). This stimulator is applied 0.5 cm outside the area of itch provocation. 15 minutes
Secondary Measurement of Cold Detection Thresholds (CDT) The tests for thermal sensation will all be conducted using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device. A thermode stimulator of 3x3 cm will be placed on the treated/placebo areas and kept in place by means of Velcro tape. During the first 8 seconds, the temperature decreases 1°C per second from a starting temperature of 32°C until the subject perceives a temperature change (cold sensation) and presses a button that will terminate the measurement and return the temperature to baseline at a rate of 5°C /s. A cut-off temperature of 0°C will be used. 15 minutes
Secondary Measurement of Cold Pain Thresholds (CPT) The tests for thermal sensation will all be conducted using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device. A thermode stimulator of 3x3 cm will be placed on the treated/placebo areas and kept in place by means of Velcro tape. During the first 8 seconds, the temperature decreases 1°C per second from a starting temperature of 32°C until the subject perceives a temperature change (cold sensation) and presses a button that will terminate the measurement and return the temperature to baseline at a rate of 5°C /s. A cut-off temperature of 0°C will be used. 15 minutes
Secondary Measurement of Warm Detection Thresholds (WDT) The tests for thermal sensation will all be performed using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device. A thermode stimulator of 3x3 cm will be placed on the treated/placebo areas and kept in place by means of Velcro tape. During the first 8 seconds, the temperature raises 1°C per second from a starting temperature of 32°C until the subject detects a painful sensation and presses a button that will terminate the measurement and return the temperature to baseline at a rate of 5°C /s. A cut-off temperature of 52°C will be used. 15 minutes
Secondary Measurement of Heat Pain Thresholds (HPT) The tests for thermal sensation will all be performed using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device. A thermode stimulator of 3x3 cm will be placed on the treated/placebo areas and kept in place by means of Velcro tape. During the first 8 seconds, the temperature raises 1°C per second from a starting temperature of 32°C until the subject detects a painful sensation and presses a button that will terminate the measurement and return the temperature to baseline at a rate of 5°C /s. A cut-off temperature of 52°C will be used. 15 minutes
Secondary Measurement of Pain to Supra-threshold Heat Stimuli The tests will be conducted by using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device. A thermode stimulator of 3x3 cm will be placed on the treated/placebo areas and kept in place by means of Velcro tape. The subjects will have to rate the pain to two suprathreshold heat pain stimuli (starting and ending at 32°C with an increase and decrease of 5°C and 3 s plateau at 50°C). 15 minutes
Secondary Measurement of Mechanical Pain Thresholds (MPT) This test is conducted using a pin-prick set (Aalborg University, Aalborg). 15 minutes
Secondary Measurement of Mechanical Pain Sensitivity (MPS) This test is conducted using a pin-prick set (Aalborg University, Aalborg). 15 minutes
Secondary Touch Pleasantness (TP) Pleasant touch sensation measured using a standardized sensory brush (SENSELab Brush-05, Somedic AB, Hörby, Sweden) exerting a force of 200 to 400 mN. 15 minutes
See also
  Status Clinical Trial Phase
Completed NCT01683552 - Aprepitant in the Management of Biological Therapies-related Severe Pruritus Phase 2
Completed NCT02075632 - Study to Evaluate Product Duration of Use Experience With Alclometasone Dipropionate Cream Phase 2
Completed NCT04076865 - Evaluation of the Effect Induced by Repeated Administration of Topical Local Anaesthetic (EMLA) on Itch N/A
Completed NCT04588532 - Characterization of BAM8-22 as a New Surrogate Model of Non-histaminergic Itch N/A
Enrolling by invitation NCT05195177 - Testing Protocol to Efficiently Induce Itch N/A
Withdrawn NCT03943407 - Characterization of the Toll-like Receptor 7-agonist Imiquimod 3.75% as a New Surrogate Model of Itch N/A
Completed NCT04858360 - Inhibition of Non-histaminergic Pruritus Applied Using 3 Different Pruritogens N/A
Completed NCT04635254 - The Effect of Halophyte-based Cream on Pain and Itch N/A
Not yet recruiting NCT06201715 - Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis N/A
Completed NCT06036589 - Characterization of Bovine Adrenal Medulla as a Model of Non-histaminergic Itch N/A
Completed NCT04554888 - Characterization of New Human Models of Non-histaminergic Itch and Their Interaction With the TRPM8 Receptor N/A
Completed NCT04387851 - Learning Mechanisms for Placebo and Nocebo Studies on Somatosensory Sensations: a Systematic Review and Meta-analysis.
Completed NCT03928223 - The Color of Itch; Itch Modification by Color Viewing
Not yet recruiting NCT06245564 - Effect of Ketamine, Amitriptyline and Their Combination on Histaminergic and Non-histaminergic Itch N/A
Completed NCT03576053 - A Mechanistic Evaluation of the Interactions Between Thermoceptive and Pruriceptive Sensory Processing N/A
Completed NCT04700007 - Evaluation of Peripheral Itch Mechanisms Following Injection of Morphine (Second Sub-Project) N/A
Terminated NCT02828787 - Central Mechanisms of Chronic Pruritus: Functional and Structural Brain Imaging. N/A
Not yet recruiting NCT04197440 - Characterization of Bovine Adrenal Medulla (BAM8-22) as a New Surrogate Model of Non-histaminergic Itch N/A
Completed NCT04115462 - A Relation of Morphine-induced Itch and Pain Processing N/A
Completed NCT05249387 - Characterization of Bovine Adrenal Medulla as a New Surrogate Model of Non-histaminergic Itch N/A